Integrum receives a Unitary Patent for Neuromotus in the EU
Mölndal, Sweden, October 10, 2023 – Integrum (publ) (Nasdaq First North Growth Market: INTEG B) today announces that the company has received a Unitary Patent approval pertaining to Neuromotus[TM] – a clinical innovation aimed at treating patients suffering from Phantom Limb Pain. The new patent process, which was installed by the EU in June 2023, grants immediate proprietary rights to Integrum in 17 separate European countries.Integrum develops Neuromotus[TM], an innovative therapy designed to treat patients suffering from phantom pain. The therapy is based on a non-invasive technology